Sandton Oncology Centre, Sandton, Parklands, Johannesburg, South Africa.
Curr Treat Options Oncol. 2011 Dec;12(4):412-23. doi: 10.1007/s11864-011-0163-3.
Bisphosphonates have emerged as an important tool in the supportive care of women with early breast cancer. Whereas traditionally, these drugs have been part of the treatment of osseous metastasis, the key role of bisphosphonates in preserving bone health in patients with early breast cancer cannot be overemphasised. Currently the most established use of bisphosphonates in early breast cancer patients is in women receiving hormonal blockade, mostly aromatase inhibitors (AI), with concomitant osteopenia. To that end, it is recommended that every woman undergo a Dual Energy X-Ray absorptiometry (DEXA) scan before commencement of an AI and annually during the treatment duration. In addition, unless contraindicated, all women should receive calcium and Vitamin D supplementation. The use of bisphosphonates as part of the adjuvant therapy strategy, regardless of baseline bone density condition, has produced thought-provoking results, although this is not yet considered standard clinical practise.
双膦酸盐已成为早期乳腺癌女性支持治疗的重要手段。传统上，这些药物是治疗骨转移的一部分，但双膦酸盐在保护早期乳腺癌患者骨骼健康方面的关键作用怎么强调都不为过。目前，双膦酸盐在早期乳腺癌患者中的最主要用途是在接受激素阻断治疗的患者中，尤其是芳香酶抑制剂（AI）联合骨质疏松症患者。为此，建议每位接受 AI 治疗的患者在开始治疗前和治疗期间每年进行一次双能 X 射线吸收法（DEXA）扫描。此外，除非有禁忌症，所有女性都应接受钙和维生素 D 的补充。双膦酸盐作为辅助治疗策略的一部分，无论基线骨密度如何，都取得了引人深思的结果，尽管这尚未被视为标准临床实践。
